261 related articles for article (PubMed ID: 33886073)
1. Trophoblast Cell Surface Antigen 2 (Trop-2) Protein is Highly Expressed in Salivary Gland Carcinomas and Represents a Potential Therapeutic Target.
Wolber P; Nachtsheim L; Hoffmann F; Klußmann JP; Meyer M; von Eggeling F; Guntinas-Lichius O; Quaas A; Arolt C
Head Neck Pathol; 2021 Dec; 15(4):1147-1155. PubMed ID: 33886073
[TBL] [Abstract][Full Text] [Related]
2. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.
Zeybek B; Manzano A; Bianchi A; Bonazzoli E; Bellone S; Buza N; Hui P; Lopez S; Perrone E; Manara P; Zammataro L; Altwerger G; Han C; Tymon-Rosario J; Menderes G; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin A
Sci Rep; 2020 Jan; 10(1):973. PubMed ID: 31969666
[TBL] [Abstract][Full Text] [Related]
3. Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.
Perrone E; Manara P; Lopez S; Bellone S; Bonazzoli E; Manzano A; Zammataro L; Bianchi A; Zeybek B; Buza N; Tymon-Rosario J; Altwerger G; Han C; Menderes G; Huang GS; Ratner E; Silasi DA; Azodi M; Hui P; Schwartz PE; Scambia G; Santin AD
Mol Oncol; 2020 Mar; 14(3):645-656. PubMed ID: 31891442
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
Han C; Perrone E; Zeybek B; Bellone S; Tymon-Rosario J; Altwerger G; Menderes G; Feinberg J; Haines K; Muller Karger ME; Bianchi A; Zammataro L; Manzano A; Bonazzoli E; Manara P; Buza N; Hui P; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Lopez S; Santin AD
Gynecol Oncol; 2020 Feb; 156(2):430-438. PubMed ID: 31839338
[TBL] [Abstract][Full Text] [Related]
5. TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma.
Seok JY; Astvatsaturyan K; Peralta-Venturina M; Lai J; Fan X
Int J Surg Pathol; 2021 Jun; 29(4):368-377. PubMed ID: 33289434
[TBL] [Abstract][Full Text] [Related]
6. CD138 Is Expressed in Different Entities of Salivary Gland Cancer and Their Lymph Node Metastases and Therefore Represents a Potential Therapeutic Target.
Mayer M; Nachtsheim L; Hoffmann F; von Eggeling F; Guntinas-Lichius O; Prinz J; Klußmann JP; Quaas A; Arolt C; Wolber P
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012301
[TBL] [Abstract][Full Text] [Related]
7. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
Ocean AJ; Starodub AN; Bardia A; Vahdat LT; Isakoff SJ; Guarino M; Messersmith WA; Picozzi VJ; Mayer IA; Wegener WA; Maliakal P; Govindan SV; Sharkey RM; Goldenberg DM
Cancer; 2017 Oct; 123(19):3843-3854. PubMed ID: 28558150
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.
Goldenberg DM; Sharkey RM
MAbs; 2019; 11(6):987-995. PubMed ID: 31208270
[TBL] [Abstract][Full Text] [Related]
9. Impact of Spatially Heterogeneous Trop-2 Expression on Prognosis in Oral Squamous Cell Carcinoma.
Erber R; Spoerl S; Mamilos A; Krupar R; Hartmann A; Ruebner M; Taxis J; Wittenberg M; Reichert TE; Spanier G; Spoerl S
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008509
[TBL] [Abstract][Full Text] [Related]
10. Expression of Mucins in Different Entities of Salivary Gland Cancer: Highest Expression of Mucin-1 in Salivary Duct Carcinoma : Mucin-1 - highest expression in Salivary Duct Carcinoma.
Wolber P; Mayer M; Nachtsheim L; Prinz J; Klußmann JP; Quaas A; Arolt C
Head Neck Pathol; 2022 Sep; 16(3):792-801. PubMed ID: 35389164
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
Bardia A; Mayer IA; Diamond JR; Moroose RL; Isakoff SJ; Starodub AN; Shah NC; O'Shaughnessy J; Kalinsky K; Guarino M; Abramson V; Juric D; Tolaney SM; Berlin J; Messersmith WA; Ocean AJ; Wegener WA; Maliakal P; Sharkey RM; Govindan SV; Goldenberg DM; Vahdat LT
J Clin Oncol; 2017 Jul; 35(19):2141-2148. PubMed ID: 28291390
[TBL] [Abstract][Full Text] [Related]
12. Nectin-4 is frequently expressed in primary salivary gland cancer and corresponding lymph node metastases and represents an important treatment-related biomarker.
Mayer M; Nachtsheim L; Prinz J; Shabli S; Suchan M; Klußmann JP; Quaas A; Arolt C; Wolber P
Clin Exp Metastasis; 2023 Oct; 40(5):395-405. PubMed ID: 37480387
[TBL] [Abstract][Full Text] [Related]
13. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
Cardillo TM; Govindan SV; Sharkey RM; Trisal P; Arrojo R; Liu D; Rossi EA; Chang CH; Goldenberg DM
Bioconjug Chem; 2015 May; 26(5):919-31. PubMed ID: 25915780
[TBL] [Abstract][Full Text] [Related]
14. Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
Seligson JM; Patron AM; Berger MJ; Harvey RD; Seligson ND
Ann Pharmacother; 2021 Jul; 55(7):921-931. PubMed ID: 33070624
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer.
Perrone E; Lopez S; Zeybek B; Bellone S; Bonazzoli E; Pelligra S; Zammataro L; Manzano A; Manara P; Bianchi A; Buza N; Tymon-Rosario J; Altwerger G; Han C; Menderes G; Ratner E; Silasi DA; Azodi M; Hui P; Schwartz PE; Scambia G; Santin AD
Front Oncol; 2020; 10():118. PubMed ID: 32117765
[No Abstract] [Full Text] [Related]
16. First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.
Starodub AN; Ocean AJ; Shah MA; Guarino MJ; Picozzi VJ; Vahdat LT; Thomas SS; Govindan SV; Maliakal PP; Wegener WA; Hamburger SA; Sharkey RM; Goldenberg DM
Clin Cancer Res; 2015 Sep; 21(17):3870-8. PubMed ID: 25944802
[TBL] [Abstract][Full Text] [Related]
17. NR4A3 Immunohistochemistry Reliably Discriminates Acinic Cell Carcinoma from Mimics.
Wong KS; Mariño-Enriquez A; Hornick JL; Jo VY
Head Neck Pathol; 2021 Jun; 15(2):425-432. PubMed ID: 32910350
[TBL] [Abstract][Full Text] [Related]
18. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
Fenn KM; Kalinsky K
Drugs Today (Barc); 2019 Sep; 55(9):575-585. PubMed ID: 31584574
[TBL] [Abstract][Full Text] [Related]
19. TROP-2 is widely expressed in vulvar squamous cell carcinoma and represents a potential new therapeutic target.
Condic M; Egger EK; Klümper N; Kristiansen G; Mustea A; Thiesler T; Ralser DJ
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8235-8241. PubMed ID: 37067548
[TBL] [Abstract][Full Text] [Related]
20. Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers.
Vranic S; Gatalica Z
Bosn J Basic Med Sci; 2022 Feb; 22(1):14-21. PubMed ID: 34181512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]